COMP <GO>
BVS vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
Bioventus Inc. (Class A) (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BVS 2
— UNH 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
LAST: $14.87 (+1.50%) • MKT CAP: $1.25B
roic
10.40%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 88.57% | -20.27 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 10.40% | 11.47% | -1.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | 16.4x | +9.85 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.77% | 6.48% | -0.71 | UNH | /fcf-yield <GO> |
| Operating Margin | 9.50% | 4.82% | +4.68 | BVS | /operating-margins <GO> |
| Net Profit Margin | 4.00% | 3.14% | +0.86 | BVS | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 6.46% | -7.36 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 3.12 | -0.87 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.9 | 59.2 | -15.26 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | 17.1x | +34.11 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.25B | $368.83B | -$367.58B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | UNH REV | BVS GROSS % | UNH GROSS % | BVS FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $447.57B | 68.3% | 88.7% | $72.1M | $16.07B |
| FY 2024 | $573.3M | $400.28B | 67.7% | 88.3% | $37.8M | $20.70B |
| FY 2023 | $512.3M | $371.62B | — | 89.6% | $15.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
UNH // BETA 0.33